Verona Pharma bring to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive pulmonary disease. While Ohtuvayre is projected to become a blockbuster product in COPD alone, its potential extends to other respiratory disorders as well.
The post Merck Breathes Life Into Its Respiratory Prospects With $10B Deal to Buy Verona Pharma appeared first on MedCity News.
